RedHill Biopharma (RDHL) Tops Q3 EPS by 16c

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.52 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49